ArticleFrontiers in immunology2026

Disitamab vedotin (RC48) combined with PD-1 inhibitors in locally advanced or metastatic urothelial carcinoma: clinical outcomes and prognostic factors from a multicenter real-world study.

Xin Chang Zou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.